Wednesday, 21 October 2026
CVD calculator shifts risk categories, Glucose meter result mismatch risk, Salpingectomy guidance for cancer
- 01
Updated calculator shifts more Australians to intermediate CVD risk
The updated Australian cardiovascular disease risk calculator classified 26.4% of people as having intermediate five-year risk, more than double the 11.6% classified by the previous tool. Conversely, 9.7% were deemed high risk, down from 17.6%. The study analysed data from 115,873 people aged 45–74 who attended general practice between September 2020 and August 2022 and had no history of heart disease or stroke. Researchers said the reclassification meant about one in three Australians could benefit from preventive CVD medication, with treatment routinely recommended for high-risk patients and considered according to individual circumstances for those at intermediate risk. The updated calculator uses contemporary New Zealand data recalibrated for Australia and includes a diabetes-specific equation.
via RACGP newsGP
- 02
Nova removes hospital glucose meters over patient result mismatch risk
Nova Biomedical has removed StatStrip Glucose Hospital Meter Systems for a software update because glucose results could be assigned to the wrong patient. The issue affects glucose testing in hospital settings. The FDA MedWatch notice gives limited detail and does not specify affected units or further corrective action.
via FDA MedWatch
- 03
ACOG updates salpingectomy guidance for ovarian cancer prevention
The American College of Obstetricians and Gynecologists has issued a clinical practice update on opportunistic salpingectomy to prevent ovarian cancer in patients at average risk. The source gives limited detail and does not describe the updated recommendation, supporting evidence or changes from previous guidance.
via JAMA
- 04
Oral JAK inhibitors recommended for severe alopecia areata
Adults with severe alopecia areata should primarily be treated with oral Janus kinase inhibitors, according to a consensus statement. Alopecia areata is an autoimmune hair loss disorder affecting more than 7 million people in the US. The guidance was published in JAMA Dermatology. The source provides limited detail on the recommendations.
via JAMA
- 05
Pelacarsen fails to reduce cardiovascular events in phase 3 trial
Pelacarsen did not reduce the risk of adverse cardiovascular events in a phase 3 study, despite lowering lipoprotein(a) levels, the manufacturer announced. The drug remains experimental. The source provided limited detail and did not report the study population, event rates or magnitude of lipoprotein(a) reduction.
via JAMA
- 06
FDA approves four XFG-targeted COVID-19 vaccines
The US Food and Drug Administration approved four updated COVID-19 vaccines for the 2026–2027 season. The vaccines were formulated against the XFG variant. The approval represents a seasonal update to COVID-19 vaccine formulations. The source gives limited detail about the vaccines or their indications.
via JAMA
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.